Long-term Device Outcomes of Mesh Implants in Pelvic Organ Prolapse Repairs.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
7
2
2020
medline:
1
9
2020
entrez:
7
2
2020
Statut:
ppublish
Résumé
To evaluate the longer-term safety and reintervention outcomes of mesh implants in pelvic organ prolapse (POP) repairs. We conducted a population-based cohort study of women undergoing POP repairs in inpatient and outpatient surgical settings between 2008 and 2016 in New York State. Multivariable logistic regression was used based on patient and procedural characteristics and hospital volume between mesh and nonmesh groups to obtain propensity scores for each individual. Long-term safety events and reinterventions were assessed using time-to-event analysis. We identified 54,194 women undergoing POP repairs (12,989 with mesh, and 41,205 without mesh). Mean age was 59.8 (±13.1) years, and median follow-up was 4.7 years (interquartile range, 2.4-6.8 years). In the propensity score-matched 12,284 pairs of women, POP repair with mesh was associated with a higher risk of reintervention when compared with POP repair without transvaginal mesh (hazard ratio 1.40, 95% CI 1.27-1.54, P<.001). The estimated risk of undergoing a reintervention at 5 years was 8.8% (95% CI 8.2-9.3%) in the mesh group and 6.3% (5.9-6.8%) in the nonmesh group. Among patients who had reinterventions, 18.5% of those operated with mesh had a reintervention related to mesh-related complications. Even though transvaginal mesh has been removed from the market, the risk of mesh complications did not diminish over time and these women warrant close follow-up. Continued surveillance of mesh in POP repairs is essential to ensure safety for the women who have already been implanted.
Identifiants
pubmed: 32028486
doi: 10.1097/AOG.0000000000003689
pii: 00006250-202003000-00014
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-598Subventions
Organisme : FDA HHS
ID : U01 FD005478
Pays : United States
Organisme : FDA HHS
ID : U01 FD006936
Pays : United States
Références
Kaplan S, Goldstein M. F.D.A. halts U.S. sales of pelvic mesh. Available at: https://www.nytimes.com/2019/04/16/health/vaginal-pelvic-mesh-fda.html. Retrieved August 5, 2019.
Jelovsek JE. Pelvic organ prolapse in women: choosing a primary surgical procedure. Available at: https://www.uptodate.com/contents/pelvic-organ-prolapse-in-women-choosing-a-primary-surgical-procedure. Retrieved August 5, 2019.
U.S. Food and Drug Administration. Urogynecologic surgical mesh implants. Available at: https://www.fda.gov/medical-devices/implants-and-prosthetics/urogynecologic-surgical-mesh-implants. Retrieved August 5, 2019.
Medical Law Research. Transvaginal mesh legal center. Available at: http://www.tvmeshlegal.com/. Retrieved August 8, 2019.
Souders CP, Eilber KS, McClelland L, Wood LN, Souders AR, Steiner V, et al. The truth behind transvaginal mesh litigation: devices, timelines, and provider characteristics. Female Pelvic Med Reconstr Surg 2018;24:21–5.
Chughtai B, Mao J, Buck J, Kaplan S, Sedrakyan A. Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study. BMJ 2015;350:h2685.
Glazener CM, Breeman S, Elders A, Hemming C, Cooper KG, Freeman RM, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet 2017;389:381–92.
Morling JR, McAllister DA, Agur W, Fischbacher CM, Glazener CM, Guerrero K, et al. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Lancet 2017;389:629–40.
Sedrakyan A, Chughtai B, Mao J. Regulatory warnings and use of surgical mesh in pelvic organ prolapse. JAMA Intern Med 2016;176:275–7.
National Institute for Health and Care Excellence. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. Available at: https://www.nice.org.uk/guidance/ipg599. Retrieved August 5, 2019.
U.S. Food and Drug Administration. FDA strengthens requirements for surgical mesh for the transvaginal repair of pelvic organ prolapse to address safety risks. Available at: https://www.fda.gov/news-events/press-announcements/fda-strengthens-requirements-surgical-mesh-transvaginal-repair-pelvic-organ-prolapse-address-safety. Retrieved August 5, 2019.
New York State Department of Health. Statewide planning and research cooperative system (SPARCS). Available at: https://www.health.ny.gov/statistics/sparcs/. Retrieved August 5, 2019.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083–107.
Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Marjoribanks J. Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse. The Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD012079. doi: 10.1002/14651858.CD012079.
Diwadkar GB, Barber MD, Feiner B, Maher C, Jelovsek JE. Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. Obstet Gynecol 2009;113:367–73.
Government S. Transvaginal mesh implants independent review: final report. Available at: https://www.gov.scot/publications/scottish-independent-review-use-safety-efficacy-transvaginal-mesh-implants-treatment-9781786528711/pages/11/. Retrieved August 5, 2019.
Healthed. What now with vaginal mesh for prolapse? Available at: https://www.healthed.com.au/clinical-articles/what-now-with-vaginal-mesh-for-prolapse/. Retrieved August 5, 2019.
New Zealand Ministry of Health. Surgical mesh. Available at: https://www.health.govt.nz/our-work/hospitals-and-specialist-care/surgical-mesh. Retrieved August 5, 2019.
Cohen SA. Is there still a role for transvaginal mesh in treatment of pelvic organ prolapse? Curr Bladder Dysfunc 2018;13:257–61.
Schimpf MO, Abed H, Sanses T, White AB, Lowenstein L, Ward RM, et al. Graft and mesh use in transvaginal prolapse repair: a systematic review. Obstet Gynecol 2016;128:81–91.
Svabik K, Martan A, Masata J, El-Haddad R, Hubka P. Comparison of vaginal mesh repair with sacrospinous vaginal colpopexy in the management of vaginal vault prolapse after hysterectomy in patients with levator ani avulsion: a randomized controlled trial. Ultrasound Obstet Gynecol 2014;43:365–71.
American Urogynecologic Society. What is ACQUIRE? Available at: https://www.augs.org/aquire/. Retrieved August 5, 2019.
U.S. Food and Drug Administration. Medical Device Epidemiology Network Initiative (MDEpiNet). Available at: https://www.fda.gov/MedicalDevices/ScienceandResearch/EpidemiologyMedicalDevices/MedicalDeviceEpidemiologyNetworkMDEpiNet/default.htm. Retrieved August 5, 2019.
National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. Available at: https://www.nice.org.uk/guidance/ng123/chapter/recommendations#collecting-data-on-surgery-and-surgical-complications. Retrieved August 5, 2019.